Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

NUEVA YORK, NY / ACCESS Newswire / 9 de abril de 2025 / Si sufrió una pérdida en su inversión en Intellia Therapeutics, Inc. (NASDAQ:NTLA) y desea conocer una posible recuperación según las leyes federales de valores, siga el siguiente enlace para obtener más información: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=142109&wire=1

NTLA Stock Price, Quote & Chart | INTELLIA THERAPEUTICS INC (NASDAQ:NTLA)

NTLA jumps premarket on positive late-stage trial data for gene-editing therapy — retail says buy now before it’s too late

Stock Trading: Baidu Inc (BIDU) & Intellia Therapeutics Inc (NTLA) Technical Analysis Elliott Wave (amdjs4z9sD)

UBS Group AG Has $3.92 Million Stake In Intellia Therapeutics, Inc. (NASDAQ:NTLA) (YGMj6Oe9kN)

[FullVer] Intellia Therapeutics Inc. Mystery: Why Risk It? How To Profit Now #NTLA (ARh9SLo08c)

Intellia Therapeutics Stock Falls 6.52% | NTLA Market Update And Performance Review (gtDNQhnBrT)

Intellia Therapeutics, Inc. (NTLA) expected to beat earnings estimates: Can the stock move higher?

Intellia Therapeutics shares slip despite strong phase 3 data

ARK Invest’s NTLA Buy Puts Dilution And CRISPR Progress In Focus

Cathie Wood’s ARK sells AMD stock, buys Tempus AI and Intellia